Skip to main
  1. Stocks
  2. COMPASS Pathways
  3. Forecast
CMPS

COMPASS Pathways (CMPS) Stock Forecast & Price Target

COMPASS Pathways (CMPS) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 58%
Buy 33%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Compass Pathways is attractive because it has advanced COMP360 from strong clinical validation into a rolling NDA that is already under FDA review, with a potential 1H27 launch supported by federal and state rescheduling momentum and a favorable expected label. The fundamental case is reinforced by two positive Phase 3 TRD trials, supportive retreatment evidence, and a large commercial footprint of more than 8,000 interventional psychiatry centers, while management is already building reimbursement, REMS, and field infrastructure. Financially, the company ended 3Q26 with $444.0 million in cash, minimal net loss of $9.8 million, and runway into 2028, giving it the balance-sheet strength to fund launch preparation and its Phase 2b/3 PTSD program.

Bears say

Compass Pathways is vulnerable to competitive pressure because if other developers generate compelling data in the same settings where COMP360 psilocybin is expected to compete, investor enthusiasm and market share expectations could weaken. With the company still centered on a single proprietary program and one operating segment, its valuation is heavily dependent on the clinical success and differentiation of COMP360 rather than on a diversified revenue base. That concentration makes the stock fundamentally risky, since any loss of relative efficacy, safety, or momentum versus peers could modestly pressure CMPS shares.

COMPASS Pathways (CMPS) has been analyzed by 12 analysts, with a consensus rating of Buy. 58% of analysts recommend a Strong Buy, 33% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.

COMPASS Pathways (CMPS) Analyst Forecast & Price Prediction

Get the latest COMPASS Pathways (CMPS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in COMPASS Pathways (CMPS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About COMPASS Pathways (CMPS) Forecast

Analysts have given COMPASS Pathways (CMPS) a Buy based on their latest research and market trends.

According to 12 analysts, COMPASS Pathways (CMPS) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

COMPASS Pathways (CMPS)


COMPASS Pathways (CMPS) Analyst Forecast & Price Prediction

Get the latest COMPASS Pathways (CMPS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in COMPASS Pathways (CMPS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover CMPS stock data and trends